Analysis of outcomes and side effects in patients receiving radiation therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study systematically collects and analyzes patient data from those undergoing radiation therapy at the Winterthur Cantonal Hospital. It aims to assess the outcomes and adverse events associated with radiotherapy to enhance quality assurance and identify areas for improvement. By examining patient records from 2000 to 2025, the study seeks to adapt treatment protocols to minimize serious side effects in future patients. The findings will be presented and published as part of the clinical research program at the institute.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are being treated with radiotherapy at the Department of Radiation Oncology at the Winterthur Cantonal Hospital

Exclusion Criteria:

* No radiotherapy at the Department of Radiation Oncology at the Winterthur Cantonal Hospital \<16 years,\> 105 years

Where it's running

• Kantonsspital Winterthur
  Winterthur, Canton of Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Daniel Zwahlen, MD, MBA — Kantonsspital Winterthur KSW
• Study coordinator: Daniel R Zwahlen, MD, MBA
• Email: daniel.zwahlen@ksw.ch
• Phone: +41522662645

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation

  This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07802002

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Virtual vs in-person follow-up visits after radiotherapy

  This study tests whether telehealth follow-ups during radiotherapy are practical and satisfactory for patients and physicians, compared to in-person visits.

  Recruiting Shaukat Khanum Memorial Cancer Hospital & Research Centre · Lahore, Punjab Province · NCT07724548

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.